PETACH TIKVA, Israel, May 18, 2015 /PRNewswire/ --
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), an Israel-based developer of cannabinoid-based therapies targeting a variety of different indications, announced that its wholly-owned subsidiary, One World Cannabis Ltd. ("the Company"), is implementing regulation and patient-care consultancy services in New York to further advance the application and registration of medical cannabis business licenses within the existing Medical Cannabis Program.
"Our intention is to provide support to local New York businesses which intend to dispense and manufacture medical cannabis and help shepherd certifications through the Medical Cannabis Program," said Dr. Yehuda Baruch, One World Cannabis Director of Research and Regulatory Affairs and international authority on medical cannabis programs.
In addition to helping guide certified New York-based medical cannabis businesses through the regulatory framework and operating infrastructure, One World Cannabis is helping to institute the creation of a medical cannabis patients' center, consisting of patient communities. The company is also offering training and educational modules for patients - as well as physicians, caregivers and researchers - to enhance the understanding of patient-focused medical cannabis programs within existing and developing U.S. markets.
OWC also plans on a collaboration with patient groups as "Americans for Safe Access", in building and educating patients to become quality reviewers of the dispensary work and mentor other patients on how to better use medical cannabis (CTP Cannabis for Therapeutic Purposes). It is a 24/7 service and support (by phone) for the first week of use In order to help the patients counter various common side effects and thus help adherence to treatment.
"By building an infrastructure for safe care and management in using medical cannabis, we can serve as a valued partner in the process of helping medical cannabis businesses to train and educate patients, and their families, about cannabis products, treatment for medical conditions and dispensary services," added Dr. Baruch, who served as Head of the Israeli Ministry of Health's Medical Cannabis Program for 10 years.
In addition to regulatory expertise, One World Cannabis has practical research knowledge in the field of medical cannabis treatment to carry out scientific investigations into the medical effects and benefits of cannabis and the development of new products based on the results of scientific studies.
"We want to become an international hub for medical cannabis information and research, while also serving as a regulation service consultancy for advancing legislation to allow further use of medical cannabis," added Ziv Turner, CEO of One World Cannabis Ltd.
While continuing with scientific investigations into the medical effects and benefits of cannabis and the development of new programs, One World Cannabis recently released preliminary results from the first of several contracts to conduct joint preclinical and clinical research projects on the effect of several combinations of cannabinoil (CBD), tetrahydrocannabinol (THC), and research in treatment for multiple myeloma, a highly treatment-resistant form of bone marrow cancer.
Future studies for other medical conditions are currently underway.
About One World Cannabis Ltd.
One World Cannabis Ltd. ("the Company") is an Israel-based company founded in 2014 by a group of professionals with expertise in the field of medical cannabis (marijuana) treatment and medical cannabis regulatory affairs. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. The Company is a wholly owned subsidiary of OWC Pharmaceutical Research Corp. (OTCQB: OWCP).
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
SOURCE One World Cannabis Ltd. (OWC)